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Abstract
The α6-containing subtypes of the nicotinic acetylcholine receptor (nAChR) are localized to 
presynaptic terminals of the dopaminergic pathways of the central nervous system. Selective 
ligands for these nAChRs are potentially useful in both Parkinson's disease and addiction. For 
these and other goals, it is important to distinguish the binding behavior of agonists at the α6-β2 
binding site versus other subtypes. To study this problem, we apply nonsense suppression-based 
non-canonical amino acid mutagenesis. We report a combination of four mutations in α6β2 that 
yield high-level heterologous expression in Xenopus oocytes. By varying mRNA injection ratios, 
two populations were observed with unique characteristics, likely due to differing stoichiometries. 
Responses to nine known nAChR agonists were analyzed at the receptor, and their corresponding 
EC50 values and efficacies are reported. The system is compatible with nonsense suppression, 
allowing structure–function studies between Trp149 – a conserved residue on loop B found to 
make a cation-π interaction at several nAChR subtypes – and several agonists. These studies 
reveal that acetylcholine forms a strong cation-π interaction with the conserved tryptophan, while 
nicotine and TC299423 do not, suggesting a unique pharmacology for the α6β2 nAChR.
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1. Introduction
The nicotinic acetylcholine receptors (nAChR) are a type of pentameric ligand gated ion 
channel activated by the neurotransmitter acetylcholine, as well as nicotine and a wide array 
of related small molecules (Smart and Paoletti, 2012). In addition to its role at the 
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neuromuscular junction, the neuronal nAChRs are widely distributed throughout the CNS. 
To date, twelve different subunits of the neuronal nAChR have been identified, α2–α10, and 
β2–β4 (Le Novère et al., 2002). These subunits assemble in various patterns to form 
different subtypes with distinct localizations, pharmacological characteristics, and functions 
in the nervous system (Gotti et al., 2006; Zoli et al., 2014). The most commonly and widely 
expressed neuronal nAChRs in the brain are the α4β2 and α7 subtypes, and these have been 
studied in depth (Holladay et al., 1997).
The α6 subunit, which is primarily localized to the ventral tegmental area and substantia 
nigra pars compacta, is thought to form α6β2 pentamers as well as complex subtypes with 
three or more different subunits, such as α6α4β2, α6β2β3, and α6α4β2β3 (Gotti et al., 2006; 
Grady et al., 2010; Gerzanich et al.,1997). In some regions, such as the locus coerulus, α6β4 
nAChRs also form (Azam et al., 2010). Subtypes of nAChRs containing the α6 subunit have 
been of recent interest, as they are found in dopaminergic pre-synaptic terminals and thus 
influence the release of dopamine in both the nigrostriatal and mesocorticolimbic pathways 
(Holladay et al., 1997; Quik and Wonnacott, 2011; Quik and McIntosh, 2006; Yang et al., 
2009). As such, finding agonists that are selective at these subtypes, specifically the α6-β2 
binding site, could be important in studies of both Parkinson's disease and addiction.
A number of structural features are well established for nAChRs. Each subunit has an N-
terminal extracellular ligand-binding domain followed by four transmembrane helices, M1–
M4 (Miyazawa et al., 2003). Of note are the M2 helix, which lines the channel pore, (Jha et 
al., 2009) and the intracellular M3–M4 loop, which is thought to be involved in the 
trafficking of the receptor from the endoplasmic reticulum (ER) to the membrane surface 
(Kracun et al., 2008). At the interface of two adjacent subunits in the extracellular domain is 
the ligand binding site, comprised of six loops. Loops A–C are contributed by the primary 
(α) subunit and D–F by the complementary (β) subunit (Corringer et al., 2000). These loops 
contribute five conserved residues – TyrA (α6:Y93), TrpB (α6:W149), TyrC1 (α6:Y190), 
TyrC2 (α6:Y197), and TrpD (β2:W57) – that form an aromatic box responsible for binding 
the cationic moiety of agonists and antagonists. Previous studies have shown that TrpB in 
the α4-β2 interface and TyrC2 in the α7–α7 interface make a cation-π interaction with 
acetylcholine (Van Arnam and Dougherty, 2014). These results contributed to a 
pharmacophore model of the α4β2 and α7 subtypes and advanced our understanding of the 
differences in pharmacology among nAChR subtypes.
Various derivatives of α-conotoxins, disulfide-rich peptide antagonists of nAChRs, provide 
selective antagonism among α6-containing nAChRs (Azam et al., 2010; Hone et al., 2013, 
2012). These selective antagonists have provided rich information about the roles of α6-
containing subtypes in physiology and behavior. It is thought that additional information can 
be gained, and perhaps useful drugs found, among selective agonists. However developing 
agonists selective for α6-containing subtypes requires a deeper understanding of the ligand 
site, specifically how the α6-β2 binding site differs from those previously studied.
High precision studies of agonist binding in the α4β2 and α7 receptors have utilized 
nonsense suppression-based non-canonical amino acid mutagenesis in a Xenopus laevis 
oocyte expression system (Dougherty and Van Arnam, 2014). Nonsense suppression is, 
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however, relatively inefficient, with agonist-induced currents roughly an order of magnitude 
lower than produced by conventional mutagenesis, making previously reported α6-
expression systems such as chimeric subunits, and concatenated subunits unsuitable for this 
technique (Yang et al., 2009; Kuryatov et al., 2000; Letchworth and Whiteaker, 2011; Wang 
et al., 2014; Papke et al., 2008; Capelli et al., 2011; Kuryatov and Lindstrom, 2011; Ley et 
al., 2014). Here, we report a combination of four mutations that result in the controlled and 
consistent expression of α6β2 at the high levels that permit nonsense suppression and thus 
incorporation of non-canonical amino acids. Results from such experiments allow 
preliminary development of a binding model for agonists at α6β2-containing nAChRs.
2. Materials and methods
2.1. Molecular biology
Rat α6 and β2 nAChRs were in the pGEMhe vector. Site-directed mutagenesis was 
performed using the Stratagene Quik Change protocol. Circular cDNA was linearized with 
SbfI (New England Biolabs, Ipswich, MA). After purification (Qiagen, Valencia, CA), 
linearized DNA was used as a template for runoff in vitro transcription using T7 mMessage 
mMachine kit (Life Technologies, Santa Clara, CA). The resulting mRNA was purified 
(RNAeasy Mini Kit; Qiagen) and quantified by UV spectroscopy.
2.2. Ion channel expression
X. laevis oocytes (stage V to VI) were sourced from both the Caltech facility and Ecocyte 
Bio Science (Austin, TX). For expression of conventionally mutated nAChRs, oocytes were 
injected with 50 nL solution containing either 5 or 10 ng mRNA. The α6 to β2 ratio is 
reported as mass ratio. Cells were incubated for 24–48 h at 18 °C in ND96 solution (96 mM 
NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES, pH 7.5) with 0.005% (w/v) gentamycin 
and 2% (v/v) horse serum.
2.3. Non-canonical amino acid incorporation
The nitroveratryloxycarbonyl (NVOC) protected cyanomethylester forms of non-canonical 
amino acids were synthesized, coupled to the dinucleotide dCA, and enzymatically ligated 
to UAG-suppressor 74-mer THG73 tRNACUA as previously described (Dougherty and Van 
Arnam, 2014). The product was verified by MALDI time-of-flight mass spectrometry on a 
3-hydroxypicolinic acid matrix. The non-canonical amino acid-conjugated tRNA was 
deprotected by photolysis on a 500 W Hg/Xe arc lamp, filtered with Schott WG-320 and 
UG-11 filters, immediately prior to coinjection with mRNA containing the UAG mutation at 
TrpB. mRNA and tRNA were typically injected in a 1:1 or 1:2 volume ratio in a total 
volume of 50 or 75 nL respectively so that 25 ng of mRNA was injected per cell. In cases 
where observed currents were low after 48 h incubation – likely due to low receptor protein 
expression – a second injection of mRNA and tRNA was performed after 24 h.
The fidelity of non-canonical amino acid incorporation was confirmed at each site with a 
wild-type recovery experiment by charging tRNA with the wild-type residue. If this 
experiment yielded similar results to wild type, then aminoacylated tRNA incorporated the 
non-canonical amino acid and nothing else. A read-through/reaminoacylation test served as 
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a negative control by injecting unacylated 76-mer tRNA. Lack of current proved no 
detectable reaminoacylation at the TrpB site.
2.4. Whole-cell electrophysiological characterization
Acetylcholine chloride, choline chloride, carbamylcholine chloride, cytisine, and (−)-
nicotine tartrate were purchased from Sigma Aldrich (St Louis, MO), (±)-epibatidine was 
purchased from Tocris (Bristol, UK), while varenicline (Pfizer) and metanicotine and 
TC299423 (Targacept) were generous gifts. Agonist-induced currents were recorded in 
TEVC mode using the OpusXpress 6000A (Molecular Devices, Sunnyvale, CA) at a holding 
potential of −60 mV. Agonists were prepared in Ca2+-free ND96 and 1 mL was applied for 
15 s followed by a 2 min wash using buffer, except epibatidine, which was followed by a 
five minute wash. Data from dose–response experiments were normalized and averages 
were fit to the Hill equation, Inorm = 1/(1 + (EC50/[agonist])nH) where EC50 is the effective 
concentration to activate 50% of the surface receptors, and nH is the Hill coefficient.
3. Results and discussion
3.1. High-level heterologous expression of α6β2 in Xenopus oocytes
Heterologous expression of α6-containing nAChRs in Xenopus oocytes has long posed a 
challenge in studying these receptors, especially for nonsense suppression. In the present 
work, four mutations that have been previously been shown to enhance expression in other 
systems are combined in a strategy that produces functional receptors in oocytes. The first 
mutation is an L9′S mutation in the M2 helix of the α6 subunit. This mutation is analogous 
to an L9′A mutation in α4 that has been shown to increase expression and conductance, 
producing enhanced currents without affecting the pharmacological characteristics of the 
receptor (Gleitsman et al., 2009; Filatov and White, 1995; Fonck et al., 2005). However, 
unlike in studies of α4β2, the α6L9′S mutation alone was not enough to produce observable 
currents in oocytes, as demonstrated in Fig. 1A.
The M3–M4 loop in the β2 subunit is unusual – not only does it have an ER retention motif 
(RRQR) that is absent in other beta-like subunits, it also lacks a conserved ER export motif 
(LXM). Eliminating the retention motif and reconstituting the export motif has been shown 
previously to increase expression of fluorescent protein analogs of α4β2 and α6β2 in a 
mammalian cell line (Xiao et al., 2011; Srinivasan et al., 2011). Therefore, the mutations 
325LFL/LFM327 and 339RRQR/AAQA343 were incorporated into the β2 subunit, and 
α6L9′Sβ2LFM/AAQA was expressed in oocytes. This modified receptor produced observable 
currents when exposed to acetylcholine (Fig. 1B).
The waveforms produced by applying a dose of acetylcholine to α6L9′Sβ2LFM/AAQA show 
opening of the receptor followed by a quick partial closing and a sustained current until 
agonist washout. The current shape, as well as dose-response curves generated from 
α6L9′Sβ2LFM/AAQA, are inconsistent from cell to cell and typically biphasic or multiphasic, 
suggesting that multiple populations exist. The inconsistent results from this subtype along 
with an average maximum current of only 0.25 µA make α6L9′Sβ2LFM/AAQA unsuitable for 
non-canonical amino acid mutagenesis.
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In order to further increase expression levels, an L9′S mutation was added to the β2 subunit. 
The resulting α6L9′Sβ2L9′SLFM/AAQA construct was injected into oocytes and yielded 
currents consistently greater than 1 µA in response to acetylcholine, as in Fig. 1C. The 
current traces were consistent from cell to cell and showed a sustained channel opening until 
agonist washout. Dose response curves generated from α6L9′Sβ2L9′SLFM/AAQA were 
monophasic, with consistent EC50 measurements. Previous work on the mouse-muscle type 
nAChR showed leak currents to be too high to produce consistent results when all five 
subunits contained an L9′S mutation; however, the α6L9′Sβ2L9′SLFM/AAQA receptor 
(combined mutations will be indicated by α6β2‡ from here on) consistently produced 
baseline current levels much less than the observed maximum current due to agonist 
activation.
3.2. Stoichiometry control of α6β2‡ in oocytes
As part of an effort to optimize expression of α6β2‡ in oocytes, the mRNA injection ratio of 
α6 to β2 was varied. Ratios from 50:1 to 1:20 were used while keeping the total amount of 
mRNA constant at 10 ng in each cell. Two different phenotypes were observed based on 
mRNA injection ratio, as seen in Fig. 2 and Table 1: an α6-biased population that had an 
EC50 of about 0.11 µM and a Hill coefficient greater than 1, and a β2-biased population that 
had an EC50 around 0.5 µM and a Hill coefficient less than 1. A general attenuation in 
maximum currents was also observed in the β2-biased population, although this is difficult 
to quantify because of natural variations in maximum currents due to oocyte variability.
The different phenotypes observed likely result from a difference in subunit stoichiometries 
based on the mRNA ratio; that is, when more α6 mRNA is injected than β2 mRNA, more 
alpha subunits will be translated, and they will pentamerize in a combination with more 
alpha subunits than beta subunits. The tight distribution of EC50 values and Hill coefficients 
suggests a single stoichiometry is activated in the α6-biased injection ratios, while low Hill 
coefficients and high variation in EC50 values in the β2-biased ratios suggests a mixture of 
stoichiometries is present. This mRNA injection ratio effect is similar to what has been 
observed throughout the literature with α4β2 nAChRs, where two stoichiometries have been 
confirmed – (α4)3(β2)2 and (α4)2(β2)3 (Nelson et al., 2003; Moroni et al., 2006). Because it 
is better behaved, the α6-biased population will be used in binding studies conducted in this 
report.
3.3. Agonists at α6β2‡
With a controlled and uniform population of α6β2‡ receptors expressed in Xenopus oocytes 
now available, a panel of agonists was screened. The nAChR agonists acetylcholine, 
nicotine, meta-nicotine, varenicline, cytisine, choline, carbamylcholine, and epibatidine 
were evaluated. We also considered TC299423, a modestly α6β2 subtype-selective agonist 
that can serve as a probe for involvement of this subtype in α6-mediated behaviors 
(structures shown in Fig. 3) (Wall, 2015). As shown in Table 2, metanicotine, choline and 
carbamylcholine are less potent than ACh. Nicotine, varenicline, cytisine, and TC299423 are 
slightly more potent, and epibatidine has an EC50 several orders of magnitude lower than 
ACh. These trends are consistent with chimeric α6β2 expression systems previously 
reported where nicotine had a lower EC50 than acetylcholine (Wang et al., 2014). Relative 
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efficacy experiments were conducted by applying acetylcholine, followed by a dose of 
agonist sufficient to produce the maximum current in dose response experiments, and then a 
second application of acetylcholine, with wash-out steps in between. No difference in 
current between the first and second applications of ACh was seen; that is, no agonist 
demonstrated desensitization after wash-out. The efficacy values in Table 2, determined by 
dividing agonist-induced current by ACh-induced current, show these molecules act as 
partial agonists to varying degrees.
3.4. Non-canonical amino acids: ACh at TrpB
To establish the viability of this expression system and as a preliminary evaluation of the 
α6β2 agonist binding site, we tested the feasibility of using the nonsense suppression 
methodology for incorporating non-canonical amino acids into α6β2‡ receptors. As noted, 
nonsense suppression is an inefficient process, resulting in lower yields of the subunit that is 
the target of non-canonical amino acid incorporation. This could lead to altered 
stoichiometries or other complications in evaluating the agonist binding site.
Because TrpB has been shown to form a cation-π interaction in many other nAChRs (Van 
Arnam and Dougherty, 2014), this was the first residue probed using non-canonical amino 
acid mutagenesis in α6β2‡. The general strategy to probe for a cation-π interaction at a 
tryptophan employs structure–function studies, wherein the interaction is incrementally 
weakened with the addition of fluorine atoms to the indole ring side chain. As the electron 
density is withdrawn from the ring, the interaction is weakened, and an increase in EC50 is 
observed. If a cation-π interaction is present between an agonist and TrpB, a linear 
correlation will exist between the log fold-shift in EC50 for a given fluorinated tryptophan 
and the calculated binding energy between a prototype cation and that fluorinated 
tryptophan.
For initial nonsense suppression experiments, a 10:1 mRNA ratio was employed for α6β2‡. 
Considering first the fold-shifts in ACh EC50 of 5-F1Trp, 5,7-F2Trp, and 5,6,7-F3Trp 
relative to Trp, there is a clear trend (Table 3). To be certain this correlation was due to 
electronic effects, we compared three residues with a single substitution, all at the 5 position 
of the indole ring: 5-F-Trp, 5-Me-Trp and 5-Br-Trp. The steric demands of these 
substituents are Br > Me > F, while the cation-π modifying ability is F ≈ Br > Me. The data 
follow the cation-π prediction well, and cannot be interpreted as a steric effect. Fig. 4 shows 
all the data collected at TrpB. There are some outliers in the analysis. While 5-F-Trp and 6-
F-Trp show very similar results (as expected), 4-F-Trp is 3–4-fold more potent than 
expected, producing near wild type behavior. This is the only non-canonical amino acid we 
studied with a substituent in the 4 position, suggesting a special interaction at this site. Also, 
a 5-CN substituent, which is predicted to be strongly inactivating, shows the expected loss 
of function, but the effect is roughly 5-times greater than predicted. Taken as a whole, 
however, these results provide strong evidence that ACh is involved in a cation-π interaction 
with TrpB in the α6 subunit (Table 4).
As noted above, experiments involving non-canonical amino acid mutagenesis might alter 
the stoichiometry of the receptor being expressed. Therefore, non-canonical amino acid 
studies were done for a range of mRNA ratios. As shown in Fig. 5, the results from all three 
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ratios are consistent with each other. The fluorination plots have linear fits, and the Hill 
coefficients remain significantly >1. Nonsense suppression was attempted at β-biased 
mRNA ratios, but no currents were observed. We are thus confident that the nonsense 
suppression experiments are evaluating the same receptor stoichiometry as in the wild type 
experiments.
3.5. Nicotine and TC299423
The same strategy was used to evaluate whether nicotine and TC299423 make cation-π 
interactions at TrpB (Fig. 6). For nicotine, mono-substituted Trp residues show the expected 
shifts in EC50, but F2-Trp and F3-Trp are not meaningfully different from F1-Trp. This rules 
out a strong cation-π interaction. A more complicated result is seen with TC299423, but 
again, the results do not support the formation of a strong cation-π interaction. Recall that 
these exact side chain modifications were employed with ACh and produced a clear linear 
response, showing that the receptor can readily accommodate these modest structural 
changes. We cannot rule out a weak interaction between these agonists and TrpB, but the 
hallmark cation-π interaction seen in many Cys-loop receptors is clearly absent.
Prior to this work, we have performed fluorination studies of the sort described here for 26 
different combinations of drug and pentameric receptor (Dougherty and Van Arnam, 2014). 
In 22 of those cases, a cation-π interaction was found at an aromatic residue that aligns with 
TrpB. This includes the α4β2 nAChR, which is thought to play a prominent role in nicotine 
addiction, where both ACh and nicotine display a strong cation-π interaction to TrpB. The 
pattern seen here in α6β2‡ receptors, however, is reminiscent of that seen in the muscle-type 
nAChR, where ACh does but nicotine does not make a cation-π interaction (Beene et al., 
2002). The difference between muscle-type and α4β2 was explained by the residue at the i + 
4 position relative to TrpB (shown in Fig. 7); a lysine in the α4 subunit, but a glycine in α1 
(muscle-type) (Puskar et al., 2012; Xiu et al., 2009). However, the aligned residue is a lysine 
in α6, indicating the need for a different explanation. Note also that nicotine is not very 
potent at the muscle-type receptor, but it is more potent than ACh at α6β2‡, further 
highlighting the unique nature of α6-containing receptors. It thus appears that the α6β2 
nAChR presents a distinctive agonist binding site, and further detailed studies will be 
required to fully characterize it.
4. Conclusions
The combination of α6L9′S and β2L9′SLFM/AAQA subunits in the α6β2‡ construct produces 
enough current to permit nonsense suppression, allowing structure–function studies of the 
binding site at the α6-β2 interface. In these first studies, we have found that ACh makes a 
cation-π interaction to TrpB, as is often seen. Interestingly, nicotine and TC299423 do not 
make a comparable cationπ interaction. This suggests the potential for interesting and novel 
pharmacology for α6-containing nAChRs.
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Fig. 1. 
Traces of voltage clamp currents showing responses to ACh (A) α6L9′Sβ2, (B) 
α6L9′Sβ2LFM/AAQA, (C) α6β2‡, with the mutations shown graphically in (D).
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Fig. 2. 
Dose–response relationships of α6β2‡ with varying α6:β2 mRNA injection ratios show two 
distinct populations likely due to differing subunit stoichiometries.
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Fig. 3. 
Structures of all the agonists studied in this report. Electrostatic potential maps of the 
agonists involved in structure–function studies were made from HF 6-31G** calculations 
ranging from −10 (red) to +150 (blue) kcal/mol.
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Fig. 4. 
Fluorination plot of ACh at TrpB in 10:1 α6β2‡. Linear trend excludes 5-CNTrp and 4-
F1Trp and has a slope of −0.10 which indicates the presence of a strong cation-π interaction 
between the indole side chain and the cationic agonist.
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Fig. 5. 
Fluorination plot of ACh at Trp B for α6:β2 mRNA injection ratios of 10:1, 20:1, and 50:1. 
Data are consistent among ratios, confirming that these effects are due to electronics rather 
than a shift in stoichiometry.
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Fig. 6. 
Fluorination plot of ACh, nicotine, and TC299423 at TrpB. The trendline is fit to ACh data 
only. The lack of a linear trend in nicotine and TC299423 indicates these agonists do not 
make cation-π interactions with the indole side chain.
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Fig. 7. 
Alignment of Loop B in the rat α1, α2, and α6 nAChR subunits. Note the conserved Trp in 
all three subunits as well as the i + 4 Gly in α1 that aligns with a Lys in α4 and α6.
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Table 1
Dose-response relationships for various mRNA α6:β2 injection ratios.
Ratio EC50 (uM) nH Imax N
50:1 0.097 ± 0.002 1.17 ± 0.03 8.25–57.3 11
20:1 0.139 ± 0.003 1.64 ± 0.05 0.25–1.44 15
10:1 0.119 ± 0.004 1.17 ± 0.04 4.85–70.7 16
5:1 0.094 ± 0.003 1.17 ± 0.04 0.70–79.9 18
2:1 0.109 ± 0.002 1.14 ± 0.03 0.94–79.5 11
1:1 0.15 ± 0.01 1.15 ± 0.06 4.42–14.2 10
1:2 0.125 ± 0.003 1.23 ± 0.05 3.06–31.7 11
1:5 0.35 ± 0.02 0.95 ± 0.04 0.70–8.21 13
1:10 0.80 ± 0.04 0.83 ± 0.02 1.01–4.67 16
1:20 0.52 ± 0.03 0.86 ± 0.03 1.01–10.9 11
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